Appendix 3Y - Change of Director’s Interest Notice
CLINUVEL has entered a formal collaboration with four of the world’s leading...
Read More
CEO letter to shareholders
Melbourne, Australia, 19 September 2023 ASX: CUV Frankfurt Börse: UR9 Level 1...
Read More
CLINUVEL Confirms AGM Date
Melbourne, Australia, 13 September 2023 ASX: CUV Frankfurt Börse: UR9 Level 1...
Read More
CLINUVEL Vitiligo Expert Panel
CLINUVEL has entered a formal collaboration with four of the world’s leading...
Read More
SCENESSE® in adolescent EPP study
Melbourne, Australia, 5 September 2023 ASX: CUV Frankfurt Börse: UR9 Level 1...
Read More
Investor Webinar transcript
Melbourne, Australia, 30 August 2023 ASX: CUV Frankfurt Börse: UR9 Level 1...
Read More
Appendix 4G and Corporate Governance Statement
Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...
Read More
CLINUVEL delivering on a long-term strategy with increase in annual revenues, profit
Melbourne, Australia, 29 August 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...
Read More
Dividend/Distribution – CUV
Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...
Read More
Appendix 4E & Annual Report
Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...
Read More